North America, US$350m milestone payments + 10-15% royalties on annual net sales,
Rest of World, US$100m upfront + US$427m milestone payments + low teens to low twenties per cent Royalties on annual net sales.
That's A$146m cash upfront + A$1.1B milestone payments + Annual royalties (10%+, i.e 2,000 patient x US$375,000 x 10% = US$75m (A$110m) per year).
Current NEU market cap $1.75B.
I think Acadia should acquire NEU. If not, NEU should seek to dual listing on Nasdaq.
All imo.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-103
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |